Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

被引：3

作者：

Mai, Elias K. ^{[1
]}

Hielscher, Thomas ^{[2
]}

Bertsch, Uta ^{[1
]}

Schlenzka, Jana ^{[1
]}

Salwender, Hans J. ^{[3
]}

Munder, Markus ^{[4
]}

Gerecke, Christian ^{[5
]}

Duehrsen, Ulrich ^{[6
]}

Brossart, Peter ^{[7
]}

Neben, Kai ^{[8
]}

Hillengass, Jens ^{[1
]}

Raab, Marc S. ^{[1
]}

Merz, Maximilian ^{[1
]}

Baertsch, Marc-Andrea ^{[1
]}

Jauch, Anna ^{[9
]}

Hose, Dirk ^{[1
]}

Martin, Hans ^{[10
]}

Lindemann, Hans-Walter ^{[11
]}

Blau, Igor W. ^{[12
]}

Scheid, Christof ^{[13
]}

Weisel, Katja C. ^{[14
]}

Goldschmidt, Hartmut ^{[1
,15
]}

机构：

[1] Univ Clin Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[2] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[3] Asklepios Hosp Hamburg Altona, Dept Hematol & Oncol, Hamburg, Germany

[4] Univ Med Ctr Mainz, Dept Internal Med 3, Mainz, Germany

[5] Helios Hosp Berlin Buch, Dept Hematol & Oncol, Berlin, Germany

[6] Univ Clin Essen, Dept Hematol, Essen, Germany

[7] Univ Hosp Bonn, Bonn, Germany

[8] Klinikum Baden Baden, Dept Hematol & Oncol, Baden Baden, Germany

[9] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[10] Goethe Univ Frankfurt, Dept Med Hematol Oncol, Frankfurt, Germany

[11] Katholisches Krankenhaus Hagen, Dept Hematol & Oncol, Hagen, Germany

[12] Charite Univ Med Berlin, Med Clin, Berlin, Germany

[13] Univ Hosp Koln, Dept Internal Med 1, Cologne, Germany

[14] Univ Hosp Tubingen, Dept Hematol Oncol & Immunol, Tubingen, Germany

[15] Natl Ctr Tumorerkrankungen NCT Heidelberg, Heidelberg, Germany

来源：

LEUKEMIA | 2019年 / 33卷 / 01期

关键词：

D O I：

10.1038/s41375-018-0195-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：258 / 261

页数：4

共 50 条

[21] Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
Gleason, Charise
Nooka, Ajay K.
Muppidi, Samatha
Heffner, Leonard T.
Steuer, Conor E.
Kumar, Mukesh
Casbourne, Daniela
Langston, Amelia A.
Watson, Melanie
Boise, Lawrence
Kaufman, Jonathan L.
Lonial, Sagar
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[22] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
Figueiredo, Amarilis
Atkins, Harold
Mallick, Ranjeeta
Kekre, Natasha
Kew, Andrea
McCurdy, Arleigh
BLOOD, 2016, 128 (22)
[23] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Yvette N. Lamb
Drugs, 2020, 80 : 1455 - 1464
[24] An Economic Evaluation of Bortezomib-Based Induction Therapy in Double Transplant Protocols for Newly Diagnosed Multiple Myeloma Patients
Wang, Si-Tien
Duh, Mei Sheng
Huang, Hui
White, Leigh Ann
Chang, Eva
Esseltine, Dixie-Lee
Marantz, Jing L.
BLOOD, 2008, 112 (11) : 831 - 832
[25] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Lamb, Yvette N.
DRUGS, 2020, 80 (14) : 1455 - 1464
[26] Treatment of transplant-eligible patients with newly diagnosed multiple myeloma
Nakaseko, Chiaki
ANNALS OF ONCOLOGY, 2017, 28
[27] Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Shaji Kumar
Current Hematologic Malignancy Reports, 2011, 6 : 104 - 112
[28] Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Kumar, Shaji
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (02) : 104 - 112
[29] Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Mai, Elias K.
Bertsch, Uta
Pozek, Ema
Fenk, Roland
Besemer, Britta
Hanoun, Christine
Schroers, Roland
von Metzler, Ivana
Haenel, Mathias
Mann, Christoph
Leypoldt, Lisa B.
Heilmeier, Bernhard
Huhn, Stefanie
Vogel, Sabine K.
Hundemer, Michael
Scheid, Christof
Blau, Igor W.
Luntz, Steffen
Weinhold, Niels
Tichy, Diana
Holderried, Tobias A. W.
Trautmann-Grill, Karolin
Gezer, Deniz
Klaiber-Hakimi, Maika
Mueller, Martin
Shumilov, Evgenii
Knauf, Wolfgang
Michel, Christian S.
Geer, Thomas
Riesenberg, Hendrik
Lutz, Christoph
Raab, Marc S.
Benner, Axel
Hoffmann, Martin
Weisel, Katja C.
Salwender, Hans J.
Goldschmidt, Hartmut
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11)
[30] Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib plus Lenalidomide plus Dexamethasone or Bortezomib plus Thalidomide plus Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Rosinol Dachs, Laura
Hebraud, Benjamin
Oriol, Albert
Colin, Anne-Laurene
Rios, Rafael
Hulin, Cyrille
Jesus Blanchard, Maria
Caillot, Denis
Sureda, Anna
Hernandez, Miguel T.
Arnulf, Bertrand
Mateos, Maria-Victoria
Macro, Margaret
San-Miguel, Jesus F.
Belhadj, Karim
Jose Lahuerta, Juan
Chen, Guang
Garelik, M. Brigid
Blade, Joan
Moreau, Philippe
Attal, Michel
BLOOD, 2018, 132

← 1 2 3 4 5 →